Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20186744 | 0.86 | HTR2A (0.39) | ALDH1A1HTR2AHTR2CKDM4E | |
| SCHEMBL18201257 | 0.74 | ABCB1 (0.35) | KDM4E | |
| SCHEMBL20186640 | 0.70 | NOD1 (0.36) | ALDH1A1 | |
| SCHEMBL24506125 | 0.66 | GRIN2B (0.62) | HTR2AHTR2C | |
| SCHEMBL20200994 | 0.64 | SLC6A4 (0.42) | HSD17B10MEN1ALDH1A1KMT2AHTR2A | |
| SCHEMBL19786102 | 0.63 | HTR2A (0.49) | HSD17B10MEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL30005815 | 0.63 | GPR3 (0.44) | HSD17B10MEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL25738058 | 0.63 | GPR3 (0.44) | HSD17B10MEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL21883969 | 0.62 | ABCB1 (0.45) | HSD17B10MEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL23116646 | 0.61 | PRCP (0.48) | HSD17B10MEN1ALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3288921-B1 | POLYCYCLIC INDOLINE AND INDOLENINE COMPOUNDS | UNIV COLORADO REGENTS (US) | 2022-06-15 | — | — | EP | disclosed |
| US-10253024-B2 | Polycyclic indoline and indolenine compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180148442-A1 | Polycyclic Indoline and Indolenine Compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253024-B2 | Polycyclic indoline and indolenine compounds | IDO1, IDO2, INMT | HSD17B10 2495/4885MEN1 760/4885ALDH1A1 2671/4885 |
| US-20180148442-A1 | Polycyclic Indoline and Indolenine Compounds | IDO1, IDO2, INMT | HSD17B10 2495/4885MEN1 760/4885ALDH1A1 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.